首页> 外文OA文献 >Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis:30-week results from the phase 3, confirmatory EGALITY study

【2h】

Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis:30-week results from the phase 3, confirmatory EGALITY study

机译：Gp2015（一种依那西普生物仿制药）与原始产品之间的多次转换不会影响慢性斑块型银屑病患者的疗效，安全性和免疫原性：第3阶段的30周结果，验证性EGaLITY研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Gerdes, S; Thaçi, D; Griffiths, C E M; Arenberger, P; Poetzl, J; Wuerth, G; Afonso, M; Woehling, H;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种 eng
中图分类

相似文献

外文文献

1. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis [J] . Griffiths C. E. M., Thaci D., Gerdes S., British Journal of Dermatology . 2017,第4期

机译：Egality研究：验证，随机，双盲研究比较GP2015的疗效，安全性和免疫原性，提出的依赖替替尼替康BioSimilar，与中度至严重的慢性牙菌斑型牛皮癣患者的发起者产品
2. Multiple switches between GP GP 2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque‐type psoriasis: 30‐week results from the phase 3, confirmatory EGALITY EGALITY study [J] . Gerdes S., Tha?i D., Griffiths C.E.M., Journal of the European Academy of Dermatology and Venereology: JEADV . 2018,第Suppla1期

机译：GP GP 2015之间的多个交换机，依赖替斯科生物酸碱单位，发起者产品不会影响慢性斑块型牛皮癣患者的疗效，安全性和免疫原性：30周的阶段3，鉴定的Egality Egality研究
3. Multiple switches between GP GP 2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque‐type psoriasis: 30‐week results from the phase 3, confirmatory EGALITY EGALITY study [J] . Gerdes S., Tha?i D., Griffiths C.E.M., Journal of the European Academy of Dermatology and Venereology: JEADV . 2018,第3期

机译：GP GP 2015之间的多个交换机，依赖替斯科生物酸碱单位，发起者产品不会影响慢性斑块型牛皮癣患者的疗效，安全性和免疫原性：30周的阶段3，鉴定的Egality Egality研究
4. Multiple switches between GP2015 an etanercept biosimilar with originator product do not impact efficacy safety and immunogenicity in patients with chronic plaque‐type psoriasis: 30‐week results from the phase 3 confirmatory EGALITY study [O] . S. Gerdes, D. Thaçi, C.E.M. Griffiths, -1

机译：依那西普生物仿制药与原始产品GP2015之间的多次切换不会影响慢性斑块状牛皮癣患者的功效安全性和免疫原性：3期临床试验30周证实性EGALITY研究
5. The EGALITY study:A confirmatory, randomised, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, versus the originator product in patients with moderate to severe chronic plaque-type psoriasis [O] . Griffiths, C E M, Thaçi, D, Gerdes, S, 2016

机译：EGaLITY研究：一项验证性，随机，双盲研究，比较Gp2015（一种拟生的依那西普生物仿制药）与中度至重度慢性斑块型银屑病患者的鼻祖产品的疗效，安全性和免疫原性

Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis:30-week results from the phase 3, confirmatory EGALITY study

著录项

引文网络

相似文献

相关主题

期刊订阅